New Enterprise Associates 16, L.P. is > 10% Shareholder of Trevi Therapeutics, Inc.. Currently has a direct ownership of 10.4 Million shares of TRVI, which is worth approximately $28.7 Million. The most recent transaction as insider was on Apr 11, 2022, when has been sold 2,631,578 shares (Common Stock) at a price of $1.9 per share, resulting in proceeds of $4,999,998. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 10.4M
0% 3M change
0% 12M change
Total Value Held $28.7 Million

New Enterprise Associates 16, L.P. Transaction History

Date Transaction Value Shares Traded Shares Held Form
Apr 11 2022
BUY
Open market or private purchase
$4,999,998 $1.9 p/Share
2,631,578 Added 20.16%
10,421,428 Common Stock
Oct 18 2021
BUY
Open market or private purchase
-
1,851,852 Added 19.21%
7,789,850 Common Stock

Also insider at

BHG
Bright Health Group Inc. Healthcare
MIRM
Mirum Pharmaceuticals, Inc. Healthcare
AKUS
Akouos, Inc. Healthcare
MRKR
Marker Therapeutics, Inc. Healthcare
MTCR
Metacrine, Inc. Healthcare
GNCA
GENOCEA BIOSCIENCES, INC. Healthcare
NEA

New Enterprise Associates 16, L.P.

> 10% Shareholder
Timonium, MD

Track Institutional and Insider Activities on TRVI

Follow Trevi Therapeutics, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells TRVI shares.

Notify only if

Insider Trading

Get notified when an Trevi Therapeutics, Inc. insider buys or sells TRVI shares.

Notify only if

News

Receive news related to Trevi Therapeutics, Inc.

Track Activities on TRVI